Understanding of the crosstalk between normal residual hematopoietic stem cells and the leukemic niche in acute myeloid leukemia

•AML remodels the bone marrow niche to make it a more permissive environment.•The has key role in suppressing hematopoietic stem cells during leukemic progression.•Future research may be exploited provide treatments for one of complications AML. Acute myeloid leukemia (AML) is heterogeneous disease, yet clinically most patients present with pancytopenia resulting from failure, predisposing them life-threatening infections and bleeding. The mechanisms by which AML mediates suppression not well known. Indeed, much effort so far been focused on how environment, less focus remodeled affects normal cells. In this perspective, we evidence (HSCs) progression perspectives future topic system comprises potent progenitor cells, our bodies lifelong supply all blood Hematopoietic are at apex hierarchy reside highly specialized niches within microenvironment, diverse complex tissue. Although tissue contains large amount also consists non-hematopoietic components such as mesenchymal stromal (MSCs) their derivatives osteoblasts adipocytes, vascularized innervated [1Méndez-Ferrer S Michurina TV Ferraro F et al.Mesenchymal haematopoietic form unique niche.Nature. 2010; 466: 829-834Crossref PubMed Scopus (2436) Google Scholar, 2Crane GM Jeffery E Morrison SJ Adult cell niches.Nat Rev Immunol. 2017; 17: 573-590Crossref (395) 3Szade K Gulati GS Chan CKF al.Where live: niche.Antioxidants Redox Signal. 2018; 29: 191-204Crossref (62) Scholar]. was originally considered reservoir cytokines, signaling mediators, oxygen regulators required but recent active crosstalk between HSCs microenvironment interaction tightly orchestrates balance proliferation differentiation [2Crane Scholar,4Yu VWC Scadden DT Heterogeneity niche.Curr Opin Hematol. 2016; 23: 331-338Crossref (58) Scholar,5Pinho Marchand T Yang al.Lineage-biased regulated distinct niches.Dev Cell. 44 (e4): 634-641Abstract Full Text PDF (113) This response various challenges system, including, limited to, inflammation, infection, hematological malignancies [6Batsivari A Haltalli MLR Passaro D al.Dynamic responses stresses.Nat Cell Biol. 2020; 22: 7-17Crossref Scholar,7Kokkaliaris KD interactions affecting malignancies.Blood Adv. 4: 3795-3803Crossref (19) review, advances understanding acute (AML). especially important considering that induced, grows, exerts many its malignant phenotypes same healthy HSCs. We recently reviewed hijacks towards own requirements several subpopulations have extensively studied, have, recently, changes immune populations. use murine models ideal understand these interactions, findings validated primary human samples. However, there minimal resident affected AML-induced remodeling microenvironment. Here review knowledge date discuss current gaps three-component interaction. disease arising accumulation mutations It common neoplastic transformation overall prognosis relatively poor [8Döhner H Weisdorf DJ Bloomfield CD leukemia.N Engl J Med. 2015; 373: 1136-1152Crossref (1912) Clinically presents undifferentiated blasts peripheral blood, [9De Kouchkovsky I Abdul-Hay M leukemia: comprehensive 2016 update.Blood Cancer J. 6: e441Crossref (637) Upon closer inspection, clear quiescent, chemoresistant (LSCs) phenotypically different bulk blast populations divergent roles [10Galen P Van Hovestadt V Ii MHW al.Single-cell RNA-seq reveals Hierarchies relevant immunity article single-cell Reveals hierarchies immunity.Cell. 2019; 176 (e24): 1265-1281Abstract (325) Scholar,11Boyd AL Aslostovar L Reid al.Identification chemotherapy-induced leukemic-regenerating transient vulnerability recurrence.Cancer 34 (e5): 483-498Abstract (83) At diagnosis, failure (severely reduced neutrophil, platelet, red counts), leading severe bleeding infections. severity often exacerbated intensive chemotherapy, further death [12Kantarjian O'Brisn Cortes al.Results chemotherapy 998 age 65 years or older high-risk myelodysplastic syndrome: predictive prognostic outcome.Cancer. 2006; 106: 1090-1098Crossref (505) Originally, presumed simply outcompetes evicts niche, early investigations using serum identified essential secreted proteins hematopoiesis [13Hall PD Benko Hogan KR Stuart RK influence tumor necrosis factor-α interleukin-6 concentrations nonhematologic toxicity hematologic recovery myelogenous leukemia.Exp 1995; 1256-1260PubMed conceptually similar reports juvenile chronic (JCML) [14Freedman MH Cohen Grunberger al.Central tumour factor, GM-CSF, interleukin 1 pathogenesis leukaemia.Br Haematol. 1992; 80: 40-48Crossref (98) Scholar] multiple myeloma [15Hayashi Hideshima Nguyen AN al.Transforming growth factor β receptor kinase inhibitor down-regulates cytokine secretion microenvironment.Clin Res. 2004; 10: 7540-7546Crossref (92) Scholar], previous work revealed an enrichment patients, PDX models, indicating conserved blockage development [16Miraki-Moud F, Anjos-Afonso Hodby KA, al. does deplete induces cytopenias impeding differentiation. Proc Natl Acad Sci USA. 110:13576–581.Google These others described cycle (HSPCs) caused predominantly factors transforming (TGFβ) α (TNFα) Scholar,14Freedman Scholar,17Iversen PO Wiig Tumor adiponectin interstitial fluid inhibit hematopoiesis.Clin 2005; 11: 6793-6799Crossref (36) Scholar,18Vinante Rigo Tecchio C al.Serum levels p55 p75 soluble TNF receptors adult leukaemia diagnosis: correlation clinical biological features outcome.Br 1988; 102: 1025-1034Crossref (IL-6) treatment cycles, comparatively low IL-6 had increased platelet compared high levels, TNFα fewer unit transfusions mechanism action molecules HSPCs notably through expression cycle-suppressing (p19, p21, Erg1–-3) [19Cheng Hao Liu Y al.Leukemic infiltration novel Egr3 proliferation.Blood. 126: 1302-1313Crossref (73) Scholar,20Akinduro O Weber TS Ang al.Proliferation dynamics progenitors competing space.Nat Commun. 9: 519Crossref (44) found can rescue reversing suppressive specifically block erythroid xenograft [21Zhang TY Dutta R Benard B al.IL-6 blockade reverses induced leukemia.Sci Transl 12: eaax5104Crossref (30) Despite positive avenue release exosomes carrying microRNAs AML, DPP4 exosomes, causes direct transfer cellular material HSCs, used [22Hornick NI Doron Abdelhamed al.AML suppresses releasing contain targeting c-MYB.Sci ra88Crossref (104) Scholar,23Namburi Broxmeyer HE Hong CS al.DPP4+ patients’ plasma suppress cells.Leukemia. https://doi.org/10.1038/s41375-020-01047-7Crossref (12) suppression, upon blockage, HSC transplantation potential maintained, reversible potentially explaining rapid reversal younger post-chemotherapy slower [24Burnett AK Russell NH Hills al.A randomized comparison daunorubicin 90 mg/m2 vs 60 induction: results UK NCRI AML17 trial 1206 patients.Blood. 125: 3878-3885Crossref (178) Scholar,25Büchner Schlenk RF Schaich al.Acute (AML): strategies versus standard arm—combined prospective analysis German Intergroup.J Clin Oncol. 2012; 30: 3604-3610Crossref (112) AML-dependent could beneficial, treated classic induction (targeting cycling cells) suffer cytopenia require worst cases would protect toxicity. Unfortunately, entirely refractory effects despite reported reduce pool eventually push senescence [26Ford Green W Warenski Petersen FB Effect prior mobilization.Bone Marrow Transplant. 33: 901-905Crossref (49) Scholar,27Shao Wang Chang al.Hematopoietic cancer therapy-induced long-term injury.Transl 2013; 2: 397-411PubMed surprising, consistent stress chemotoxic agents (5-fluorouracil [5FU]) inflammation/infection (lipopolysaccharide [LPS]/polyinosinic:polycytidylic acid [pIpC]) strong hematopoiesis, depletes [28Schoedel KB Morcos MNF Zerjatke al.The population dispensable steady-state hematopoiesis.Blood. 128: 2285-2296Crossref (66) 29Rossi Jamieson CHM Weissman IL Stems pathways aging cancer.Cell. 2008; 132: 681-696Abstract (695) 30Mirantes Passegué Pietras EM Pro-inflammatory cytokines: emerging players regulating function diseased hematopoiesis.Exp 2014; 329: 248-254Crossref (139) imply actually beneficial frontline treatment, new therapies targeted will need timed avoid chemotherapeutic because reconstitution potential, blocks hierarchy. mature, lineage-restricted play transit-amplifying hierarchy, contributing hemostasis. count partially accounted leukemia-induced macrophage inflammatory protein (MIPα)/chemokine (C–C motif) ligand 3 (CCL3)-dependent restricted [31Wang Gao Zhao al.Leukemia defective erythropoiesis MIP-1α/CCL3.Leukemia. 1897-1908Crossref (25) MPL thrombopoietin account neutropenic thrombocytopenic [32Rauch PJ Ellegast JM Widmer CC al.MPL predicts neutropenia thrombocytopenia.Blood. 2253-2257Crossref (28) addition, previously mentioned, appears differentiation, anemic illustrate stages mechanisms. Recovery after successful [33Goldstone AH Burnett Wheatley al.Attempts improve outcomes patients: United Kingdom Medical Research Council AML11 trial.Blood. 2001; 98: 1302-1311Crossref (353) rate allogenic [34Gisselbrecht Prentice HG Bacigalupo al.Placebo-controlled phase III lenograstim bone-marrow transplantation.Lancet. 1994; 343: 696-700Abstract (158) effect Yet, remains do recover such, outcompete few remaining requirement gold therapy implies although direct, indirect occur outlast presence chemotherapy. years, elegant sequencing studies, vivo imaging, functional approaches [35Baryawno N Przybylski Kowalczyk MS taxonomy stroma homeostasis leukemia.Cell. 177 (e16): 1915-1932Abstract (356) 36Passaro Di Tullio Abarrategi al.Increased vascular permeability contributes drug leukemia.Cancer 32 (e6): 324-341Abstract (130) 37Hanoun Zhang Mizoguchi sympathetic neuropathy promotes malignancy altered niche.Cell Stem 15: 365-375Abstract (248) 38Boyd JC Salci disrupts endogenous myelo-erythropoiesis compromising adipocyte niche.Nat 19: 1336-1347Crossref (110) wide reaching severe, loss endosteal vessels osteoblastic [39Duarte Hawkins ED Akinduro al.Inhibition rescues AML.Cell 64-77Abstract (175) deregulation adipocytic [38Boyd [37Hanoun leakiness component [36Passaro architecture severely disrupted (Figure 1). Interestingly, major though predict patient outcome [40Diaz de la Guardia Lopez-Millan Lavoie JR al.Detailed characterization stem/stromal cohort demonstrates definitive link outcomes.Stem Rep. 8: 1573-1586Abstract (57) Scholar,41Chen Hoffmeister LM Zaun outcome.Blood 5257-5268Crossref lends weight protocols aimed restoring Scholar,39Duarte Scholar].Figure 2Signals converging Red arrows indicate increase blue decrease signals marrow.View Large Image Figure ViewerDownload Hi-res image Download (PPT) known critically concentration HSC/LSC supportive regions [42Spencer JA Roussakis al.Direct measurement local live animals.Nature. 508: 269-273Crossref (726) exacerbates further. lead abundance hypoxia-inducible (HIFs) hematopoiesis. autonomous HIFs [43Rouault-Pierre Lopez-Onieva Foster al.HIF-2α protects stem/progenitors apoptosis endoplasmic reticulum stress.Cell : 549-563Abstract (135) Scholar,44Vukovic Sepulveda Subramani al.Adult lacking Hif-1α self-renew normally.Blood. 127: 2841-2846Crossref (50) later depend correct HIF [45Guarnerio Coltella Ala U al.Bone maintenance regulation hematopoiesis.Stem 794-809Abstract (23) Scholar,46Waclawiczek Hamilton Rouault-Pierre impairs via stanniocalcin leukemia.J Invest. 130: 3038-3050Crossref transcriptomic profiles homeostatic inherent difficulties involved studying encased bone, technological RNA Scholar,47Tikhonova Dolgalev Hu resolution.Nature. 569: 222-228Crossref (371) Scholar,48Baccin Al-Sabah Velten al.Combined spatial transcriptomics molecular, organization.Nat 38-48Crossref (254) imaging Scholar,49Hawkins Duarte al.T-Cell exhibits dynamic microenvironments.Nature. 538: 518-522Crossref (129) Scholar,50Lo Celso Fleming Wu JW al.Live-animal tracking individual stem/progenitor 2009; 457: 92-96Crossref (689) begun dissect molecular shed light AML-remodeled To date, MSCs studied malignancies, MSC low-risk syndrome (MDS) frank [51Kim Jekarl DW Kim al.Genetic epigenetic alterations patients.Stem 14: 177-184Crossref Scholar,52Blau Baldus Hofmann WK genetic abnormalities blasts.Blood. 2011; 118: 5583-5592Crossref (133) linked Early studies derived morphological phenotypes, rather cytogenetics hemogenic cytokines granulocyte–macrophage colony-stimulating (GM-CSF), IL-6, monocyte chemoattractant (MCP)-1 [53Huang Basu SK X exhibit aberrant elaboration.Blood 5: e302Crossref (54) Functionally, AML-derived (AML-MSCs) deficient osteogenic osteocalcin supports while reducing HSPC capacity [54Geyh Rodríguez-Paredes Jäger al.Functional inhibition leukemia.Leukemia. 683-691Crossref (93) Scholar,55Battula VL Le PM Sun al.AML-induced growth.JCI Insight. e90036Crossref (75) level, MDS- AML-MSCs specific signatures, those TGFβ Scholar,56Geyh Rodríguez-Par